SOURCE: Active Biotech

January 23, 2007 02:37 ET

RhuDex® Enters Clinical Phase IIa Trial in Rheumatoid Arthritis

LUND, SWEDEN -- (MARKET WIRE) -- January 23, 2007 -- Active Biotech AB (Stockholm; ACTI) and MediGene AG (Frankfurt; MDG) today announced the initiation of a clinical phase IIa trial of the drug candidate RhuDex® for the treatment of rheumatoid arthritis.

The placebo-controlled trial is intended to evaluate the compound's tolerability, to determine the appropriate dosage, and to provide laboratory results with indication of an anti-inflammatory effect of RhuDex®.

"The first patient has already received treatment, and trial results are expected by the end of 2007", commented Sven Andréasson, CEO of Active Biotech.

RhuDex® is a novel, orally available substance for the treatment of rheumatoid arthritis, originating from Active Biotech's patented CD80 antagonists and was out-licensed to MediGene's subsidiary Avidex Ltd in 2002.

Upon completion of this trial, an additional phase II trial with more than 200 patients is scheduled for 2008. MediGene is responsible for the clinical program and carries the related costs.

For further information, please visit MediGene's website

For Active Biotech, the agreement with Avidex/MediGene entailed initial payments, which were received in 2002 and 2005. Possible future milestone revenues related to the coming clinical program up to launch amount to GBP 5.6 million. In addition, Active Biotech will receive royalties on future sales.

Lund, January 23, 2007
Active Biotech AB (publ)

Sven Andréasson
President and CEO
Active Biotech AB is a biotechnology company focusing on research and development of pharmaceuticals. Active Biotech has a strong R&D portfolio with pipeline products focused on autoimmune/inflammatory diseases and cancer. Most advanced projects are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, as well as ANYARA for use in cancer targeted therapy for the treatment of lung-, renal- and pancreatic cancer. Further key projects in clinical development comprise the three orally administered compounds TASQ for prostate cancer 57-57 for SLE and RhuDex® for RA. In addition, the preclinical development of the I-3D project is being conducted in cooperation with Chelsea Therapeutics.
Active Biotech AB
Box 724, SE-220 07 Lund
Tel: +46 46-19 20 00
Fax: +46 46-19 20 50
Copyright © Hugin ASA 2007. All rights reserved.

Contact Information